← board
CLSDQ
distress 4/10 · elevated risk$0.250%today-98% from 52w high
Lead: diabetic macular edema
Revenue
pre-revenue
Liquidity
$17M
Runway
0.8 yrs
Shares 1y
-93%
Price & events
-78.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+126.4%
1M
-5.8%
3M
-78.3%
6M
-95.3%
1Y
-98.5%
2Y
-99.7%
5Y
-99.5%
All
Overview
- Market Cap
- $1.30M
- Volume
- 0
- 52 Week Range
- $0.01 – $13.27
- Total Shares
- 5.23M
- Float Shares
- 4.59M
- Short %
- 2.74%
- % Held by Insiders
- 12.29%
- % Held by Institutions
- 3.39%
- Beta
- 1.87
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2025trial initiationsecondaryavoralstat · Begin clinical trialsSEC 8-K
- December 1, 2025enrollment completesecondaryCommon stock delisted from Nasdaq, begins trading on OTC market.SEC 8-K
- 1H 2025trial initiationsecondaryPhase 3ABBV-RGX-314 · Initiate global pivotal trial in diabetic retinopathySEC 8-K
- 2025-02-01fda agreementCLS-AX · Successful end of Phase 2 meeting with FDA; alignment on Phase 3 development plan for wet AMD.SEC 8-K
- Late Q3 2024readoutPhase 2CLS-AX · Phase 2b trial data for CLS-AX in wet AMD expected late Q3 2024.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-11-18NeedhamHold
Competitors — diabetic macular edema
Recent news
- 2026-07-22Enterprise value to EBITDA forward of Clearside Biomedical, Inc. – MUN:CLM0 - TradingView
- 2026-07-15Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor - mykxlg.com
- 2026-07-14Clearside Biomedical exits Chapter 11 with Steel Partners backing - scanx.trade
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.